Aseptic abscess syndrome: a case report of a patient achieving remission with both infliximab originator and biosimilar administered at varied intervals

Front Immunol. 2024 Dec 3:15:1454813. doi: 10.3389/fimmu.2024.1454813. eCollection 2024.

Abstract

Aseptic abscesses syndrome is a rare but increasingly recognized disease that falls within the spectrum of autoinflammatory disorders. Here, we describe the case of a patient who presented with abdominal pain and fever, along with multiple abdominal and extra-abdominal abscesses, in the absence of underlying hematologic, autoimmune, infectious, or neoplastic conditions. Initially, the patient responded to glucocorticoids, but experienced several flares upon discontinuation, leading to the initiation of treatment with a TNFα inhibitor. After 5 years, an attempt to discontinue treatment resulted in a new flare of the disease. Remission was eventually achieved with a biosimilar TNFα inhibitor, albeit requiring shortened infusion intervals.

Keywords: TNFα-inhibitor; aseptic abscess syndrome; autoinflammatory disorder; biosimilar; non-medical switch.

Publication types

  • Case Reports

MeSH terms

  • Abdominal Abscess / drug therapy
  • Abdominal Abscess / etiology
  • Abscess / drug therapy
  • Adult
  • Biosimilar Pharmaceuticals* / therapeutic use
  • Female
  • Humans
  • Infliximab* / administration & dosage
  • Infliximab* / therapeutic use
  • Male
  • Remission Induction
  • Syndrome
  • Treatment Outcome

Substances

  • Infliximab
  • Biosimilar Pharmaceuticals

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.